Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Transarterial radioembolization (TARE) has emerged as a locoregional therapy to downstage tumors and expand surgical eligibility.Methods: This retrospective study included patients with HCC who underwent TARE as a bridging treatment. The primary outcomes assessed were the efficacy of TARE in facilitating curative surgery and long-term oncological outcomes, specifically overall survival (OS) and disease-free survival (DFS).Results: This study included 25 patients. 17 patients subsequently underwent surgical resection and eight underwent living-donor liver transplantation (LDLT). At a median follow-up of 33.4 months, the median disease-free survival (DFS) was 11.2 months. Patients with recurrence had a median DFS of 3.65 months, and those without recurrence had a median DFS of 27.1 months. The median overall survival (OS) for the cohort was 33.4 months. At the last follow-up, 76% of patients were alive and disease-free. Kaplan–Meier analysis demonstrated sustained OS in the LDLT group, while resection patients gradually declined within the first two years.Conclusions: TARE is an effective bridging strategy that enables curative-intent surgery in selected patients with HCC and supports favorable long-term oncological outcomes. Careful patient selection and multidisciplinary management remain essential to optimize survival benefits.
背景：肝细胞癌（HCC）仍是癌症相关死亡的主要原因。经动脉放射栓塞术（TARE）作为一种局部治疗手段，旨在降低肿瘤分期并扩大手术适应症。
方法：本回顾性研究纳入了接受TARE作为桥接治疗的HCC患者。主要评估指标为TARE促进根治性手术的疗效以及长期肿瘤学结果，包括总生存期（OS）和无病生存期（DFS）。
结果：本研究共纳入25例患者。其中17例后续接受了手术切除，8例接受了活体肝移植（LDLT）。中位随访时间为33.4个月，中位无病生存期（DFS）为11.2个月。复发患者的中位DFS为3.65个月，未复发患者的中位DFS为27.1个月。全组患者的中位总生存期（OS）为33.4个月。末次随访时，76%的患者存活且无疾病进展。Kaplan-Meier分析显示LDLT组总生存期持续稳定，而切除组患者在最初两年内生存率逐渐下降。
结论：TARE是一种有效的桥接治疗策略，可为经筛选的HCC患者实现根治性手术，并带来良好的长期肿瘤学结局。精心的患者选择和多学科管理对优化生存获益至关重要。
The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant
肿瘤(癌症)患者之家